Wound therapy startup SironRX Therapeutics has made a first close on a series A round of investment that’s expected to reach $3 million. SironRx, built on technology pioneered at Cleveland Clinic, plans to use the funding to begin human trials, which could start around the end of the year, said CEO Rahul Aras, former director […]
Many business professionals likely dream of the day when they’ll run a company as chief executive, but how many hope to lead two startups simultaneously? As CEO of Cleveland-based regenerative medicine startups Juventas Therapeutics and SironRX Therapeutics, Rahul Aras is doing just that. Each company is developing therapies based off the same technology, a growth […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
SironRX hopes to raise $2.5 million, which it would use to fund a Phase 2 clinical trial of its wound-healing technology.
Regenerative medicine company Juventas Therapeutics Inc. has received regulatory approval to begin a Phase 2 clinical trial of critical limb ischemia patients.
Clinical-stage regenerative medicine company Juventas Therapeutics Inc.–a Cleveland Clinic spin-off initially named AccelleRX–has started enrolling patients in a Phase 1 clinical trial to evaluate the safety and efficacy of its leading stem cell factor for treating heart failure. In preclinical studies of heart failure in pigs, JVS-100, as the factor is known, significantly increased cardiac […]